my account log out | |
Magic™ TCR Repertoire Analysis for Minimal Residual Disease Quantification |
Create: 03/26/2019 |
Expired Date: | never |
Category: | Drugs&Pharmaceutical [Health&Medical&Pharmaceutical] |
Message: | Creative Biolabs has applied our advanced Magic™ TCR repertoire analysis platform to MRD quantification for highly accurate and reproducible results. MRD is the name given to small numbers of leukemic cells or other cancer cells that remain in the patient during treatment or after treatment when the patient is in remission. It is the major cause of relapse in cancer and leukemia. https://www.creative-biolabs.com/tcr-repertoire-analysis-for-minimal-residual-disease-quantification.html |
City: | Shirley[US] |
Location: | |
Feb 01 2023 | VBS++ (with Ca and Mg) Buffer | 214 | |
Feb 01 2023 | GVBE Buffer | 214 | |
Feb 01 2023 | GVB++ (with Ca and Mg) Buffer | 221 | |
Feb 01 2023 | Hemolysin (Rabbit Anti-Sheep Cell Hemolysin) | 208 | |
Aug 30 2019 | Anti-HSV-2 gH Antibody | 392 | |
Aug 30 2019 | Anti-L. major LPG Antibody | 476 | |
Aug 30 2019 | Anti-DENV-1 Antibody | 385 | |
Aug 30 2019 | Anti-BPV-1 L1 Antibody | 401 | |
Aug 30 2019 | Anti-H3N2 HA Antibody | 387 | |
Aug 30 2019 | Anti-EIAV env Antibody | 411 |
Copyright © toextrade Inc. All rights reserved. Contact us |